Pitch for Investment

Latest Insights, Interviews, News, and Resources.

The latest news from UKI2S and our portfolio companies

Scientific Research

EPSRC Announces £440m for Doctoral Training

15th February 2019

Funding for 75 Centres for Doctoral Training (CDTs) under the umbrella of the Engineering and Physical Sciences Research Council (EPSRC) was announced last week.
Crescendo

Eagle Genomics Closes $3.5M Investment

30th January 2019

Microbiome discovery platform company Eagle Genomics announces funding of $3.5M led by the Environmental Technologies Fund (ETF Partners), a European growth fund specialising in promoting sustainability through innovation.
Brain

Tech to Watch 2019 – AI

24th January 2019

Artificial Intelligence, or machine learning, is steadily working its way into our lives. Businesses are increasingly confident of using AI to increase customer engagement with giants Microsoft, Apple, Google and Amazon leading the charge.
microbes

Tech to Watch 2019 – The Microbiome

9th January 2019

The relationship between human health and the microbes that live on and within us (our microbiome) is increasingly understood, particularly for the microbes…
Medication

Eastern Biopharma Industry and Investment

20th December 2018

The BioCentury China Healthcare Summit saw thought leaders from industry, academia and finance meet in Shanghai to learn about China’s burgeoning biopharma ecosystem.
Newspaper

December UKI2S Digest

13th December 2018

Headlines: CRISPR Ethics. Life Science Sector Deal Announced…
Scientist

Microsoft Genomics ventures into the microbiome with Eagle Genomics

16th October 2018

Read the full press release here…
Circuit

Eagle Genomics Gains Microsoft Co-Sell Status for Microbiome Mapping AI Platform

13th September 2018

Eagle Genomics has landed a prestigious co-sell partnership with Microsoft for their knowledge discovery platform.

Suited

Crescendo Biologics Strengthens its Management with the Appointment of Dr Pavel Pisa as Chief Medical Officer

11th September 2018

Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Pavel Pisa, MD, PhD, has been appointed as…
Shop window

Eagle Genomics Lands Co-Sell Status as Part of Microsoft for Startups Programme

5th September 2018

Eagle Genomics joins a specialised group of high-growth startups, earning co-sell status as part of Microsoft’s new programme to collaborate on intensive joint sales and go-to-market initiatives.
Medication

UKI2S announces seed investment in Cagen, a pioneering engineering biology company using protein nanocages

10th August 2018

UK Innovation & Science Seed Fund (UKI2S) and Imperial Innovations announce the launch of Cagen, a company focused on innovative uses of protein nanocages.
Seminar

UKI2S Portfolio Company Marketing Seminar

23rd May 2018

Watch the video.
Taking notes

Eagle Genomics raises $1m in funding first close and announces senior leadership changes

3rd May 2018

Software leader in the field of genomic data and bioinformatics analysis poised for growth.
Lab work

UK biotech to manufacture novel medicines for Inflammatory Bowel Disease using spores of gut bacteria

27th March 2018

Three leading British biotechnology businesses have obtained grant funding from Innovate UK to investigate the manufacture of a new class of medicines…
Money

Funding New Spinouts & Backing an Industry Leader

14th March 2018

We work closely with our partner laboratories to identify commercial opportunities arising from their world-class research and we are excited to announce investments in…
Glialign CEO John Sinden

UCL Technology Fund and UK Innovation & Science Seed Fund invest in cell therapy company Glialign

11th March 2018

The UCL Technology Fund (UCLTF), UK Innovation & Science Seed Fund (UKI2S), alongside support from Innovate UK, have invested in UCL spinout company Glialign Ltd…
Synthace research

CellCentric’s first-in-class p300/CBP inhibitor drug CCS1477; capsule production complete ready for the clinic

8th March 2018

Production of CCS1477 in capsule form is now complete, ahead of forthcoming first-in-human clinical trials to investigate the novel drug’s tolerability and efficacy…
Money

Early Stage Science Companies Secure Investment

7th March 2018

The UK Innovation & Science Seed Fund (UKI2S) – formerly known as Rainbow Seed Fund – has invested via Innovate UK’s £8.5m accelerator, which combines equity and grant funding.
Pireta

UK Innovation & Science Seed Fund Backs Pireta

23rd October 2017

A Smart Textiles Technology Developed at the National Physical Laboratory.
Crescendo

UKI2S’ Success Working with Innovate UK Accelerator Program

6th October 2017

UK Innovation & Science Seed Fund has closed its first investment (to be announced soon) originating from the Fund’s participation in the Innovate UK (IUK) Investment Accelerator pilot…
Test Tubes

£160m funding boost for British life sciences

14th September 2017

Investing in the UK life science ecosystem.
Colorifix wins UKI2S award at bio-start competition

Colorifix Wins UK Innovation & Science Seed Fund “Breaking New Ground” Award at Bio-start Competition

12th July 2017

Eco-friendly engineering biology start-up revolutionising dyeing process.
Cityscape

Bio-start announces the 15 companies that will be joining the UK’s first Engineering Biology accelerator programme

10th July 2017

UK Innovation & Science Seed Fund is proud to sponsor the UK’s first Engineering Biology accelerator programme announced by Bio-start.
Ideas

Thinking about the upside for the UK in innovation

6th July 2017

As you may have read in our Chairman Ian Taylor’s recent blog “For the Love of Spinouts,” you’ll know that UKI2S hosted an event with the Innovate UK Catapult network…
UKI2S

© UKI2S and Future Planet Capital (Ventures) Limited. All Rights Reserved. UKI2S is managed by Future Planet Capital (Ventures) Limited which is Authorised and Regulated in the UK by the Financial Conduct Authority FRN 148549. Registered in England and Wales. Company Number 2500898. Registered Address: Future Planet Capital (Ventures) Limited, 1 Scott Place, 2 Hardman Street, Manchester, M3 3AA.

Stay updated

UKI2S
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.